TerminatedPhase 3NCT02317562
Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Principal Investigator
- Eduardo NOBILE-ORAZIO, MDIRCCS Instituto Clinico Humanitas, Milano, Italy
- Intervention
- I10E(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2017
Study locations (30)
- CHU de Bordeaux - Hôpital Pellegrin, Bordeaux, France
- Hôpital général du CHU de Dijon, Dijon, France
- CHU de Nice - Hôpital l'Archet, Nice, France
- CHU paris - Hôpital Pitié salpétrière, Paris, France
- CHU de Saint Etienne - Hôpital Nord, Saint-Etienne, France
- Hôpital de Hautepierre, Strasbourg, France
- IRRCS Azienda Ospedaliera Universitaria, Genova, Italy
- IRCCS Instituto Clinico Humanitas, Milan, Italy
- IRRCS Istutito Nazionale Neurologico Besta, Milan, Italy
- Ospedale San Raffaele IRCCS, Milan, Italy
- Azienda Ospedaliera Universitaria di Padova, Padua, Italy
- Università Cattolica del sacro Cuore, Roma, Italy
- Azienda Ospedaliera Universitaria san Giovanni, Torino, Italy
- Hospital de la santa creu i Sant Pau, Barcelona, Spain
- Hospital General Universitario Gregorio, Madrid, Spain
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02317562 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →